445 related articles for article (PubMed ID: 36512081)
21. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
23. Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study.
Stefoni V; Pellegrini C; Argnani L; Corradini P; Dodero A; Orsucci L; Volpetti S; Zinzani PL
Hematol Oncol; 2022 Apr; 40(2):307-309. PubMed ID: 35023190
[No Abstract] [Full Text] [Related]
24. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.
Oberic L; Delzor F; Protin C; Perriat S; Laurent C; Grand A; Canonge JM; Borel C; Gauthier M; Ysebaert L; Puisset F
J Oncol Pharm Pract; 2021 Oct; 27(7):1730-1735. PubMed ID: 33100177
[TBL] [Abstract][Full Text] [Related]
26. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
[TBL] [Abstract][Full Text] [Related]
27. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
28. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
Han TH; Chen R; Advani R; Berryman RB; Smith SE; Forero-Torres A; Rosenblatt JD; Smith MR; Zain J; Hunder NN; Engert A
Cancer Chemother Pharmacol; 2013 Jul; 72(1):241-9. PubMed ID: 23719719
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
Scott LJ
Drugs; 2017 Mar; 77(4):435-445. PubMed ID: 28190142
[TBL] [Abstract][Full Text] [Related]
30. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
Bhatt S; Ashlock BM; Natkunam Y; Sujoy V; Chapman JR; Ramos JC; Mesri EA; Lossos IS
Blood; 2013 Aug; 122(7):1233-42. PubMed ID: 23838350
[TBL] [Abstract][Full Text] [Related]
31. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
Gualberto A
Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
[TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
34. Role of CD30 targeting in malignant lymphoma.
Kumar A; Younes A
Curr Treat Options Oncol; 2014 Jun; 15(2):210-25. PubMed ID: 24570331
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
36. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.
Horwitz SM; Advani RH; Bartlett NL; Jacobsen ED; Sharman JP; O'Connor OA; Siddiqi T; Kennedy DA; Oki Y
Blood; 2014 May; 123(20):3095-100. PubMed ID: 24652992
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.
Oka S; Ono K; Nohgawa M
Anticancer Drugs; 2020 Jun; 31(5):536-539. PubMed ID: 31934889
[TBL] [Abstract][Full Text] [Related]
38. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
39. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Vaklavas C; Forero-Torres A
Ther Adv Hematol; 2012 Aug; 3(4):209-25. PubMed ID: 23606932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]